The Best Organic Mattress Toppers for Your Nontoxic Bed
WIRED TIRED Dunlop and Talalay latex versions available Probably too firm for side sleepers Excellent breathability Good amount of contouring to relieve pressure points
Avocado's Eco Mattress Topper is its cheapest mattress topper, but certainly doesn't feel like it. This latex topper is incredibly light and springy, making even my super-firm mattress feel soft and contouring without that strange sinking sensation you can get on other soft mattress toppers.
There are two feel options, Medium and Plush, both of which use different types of latex. I tested the Medium, which still gave me plenty of softness, and the GOLS-certified (Global Organic Latex Standard) organic Dunlop latex was very airy to sleep on. The Plush version uses Talalay Latex, which generally offers a softer feel and more breathability, making for slightly cooler sleeping. Both feature a GOTS-certified organic cotton cover with a hidden underside zipper. — Nena Farrell
Prices range from $199 for a twin to $399 for a California king. Specs Composition GOLS-certified Dunlop latex or FSC certified Talalay latex. GOTS-certified organic cotton cover Firmness Medium, Plush Height 2, 3 inches Cover Not removable or washable Trial period 100 nights
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
POP Launches Canine Health Study with Innovative Pet Lab and Embark to Advance Data-Driven Pet Wellness
New U.S.-based study will explore the impact of gut-focused nutrition, DNA insights, and activity tracking on canine immunity and long-term vitality HOUSTON, Aug. 14, 2025 /PRNewswire/ -- Pet wellness company POP today announced the launch of a 90-day canine health study in collaboration with Innovative Pet Lab, and Embark Veterinary. Designed to explore how personalized nutrition, biological data, and behavior tracking can support immune health and long-term vitality, the study will enroll up to 100 dogs from across the United States. Participants will receive over $600 in free health tools, including POP's science-backed supplement POP-Topper, Innovative Pet Lab's gut biomarker test kits, and Embark's DNA test. The study will also deliver a personalized health report at the end of the 90 days, combining insights from multiple data sources. "Dogs can't always tell us when something's off—but their biology and behavior can," said Alan Tsui, Co-Founder of POP. "We're combining cutting-edge diagnostics, personalized nutrition, and real-world data to give pet parents a clearer picture of their dog's health—and contribute to a future where all dogs live longer, healthier lives." POP, short for "Power of Pets," launched in 2024 to address the growing need for preventative pet health solutions rooted in science and personalization. Its flagship product, POP-Topper, is a functional food topper formulated with clinically studied ingredients that support gut health and reduce inflammation. Innovative Pet Lab will provide two at-home gut health test kits per participant to measure key markers like calprotectin, zonulin, and SIgA. Embark Veterinary, the global leader in dog DNA testing, will offer breed, trait, and genetic risk profiling to support individualized interpretation. This comprehensive study will investigate how a personalized protocol—combining diet, gut diagnostics, DNA, and behavior data—can inform smarter, more proactive dog care. Results will also contribute to future research on the early detection and prevention of chronic diseases like IBD, arthritis, and obesity. Enrollment is now open for dog owners in the U.S. with dogs aged 1–6 years. Participants must commit to feeding POP-Topper daily, submitting samples, and completing a series of surveys and weekly logs. Those who complete the study will receive a full refund of their $99 deposit. To learn more or apply, visit: About POPPOP (Power of Pets) is a next-generation pet health company dedicated to extending canine healthspan—the years dogs spend thriving, not just surviving. POP combines science-backed supplements and personalized diagnostics to help pet parents make better health decisions. Learn more at About Innovative Pet LabInnovative Pet Lab is a leader in canine gut health screening tests. Their at-home testing kits translate microbiome and immune biomarkers into actionable insights, empowering earlier intervention and improved long-term outcomes for dogs. About Embark VeterinaryEmbark offers the most comprehensive dog DNA test on the market. Developed by veterinarians and geneticists, Embark provides breed breakdowns, health risk screening, and trait insights to support proactive care. View original content to download multimedia: SOURCE POP LABS (Pet Longevity Research Limited) Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
23 minutes ago
- Medscape
FDA Panel Seeks More Data on Filler Use in Decolletage Area
A FDA advisory panel recommended that manufacturers of dermal fillers collect more information on use in the decolletage area of the body and said that some patients might be at higher risk of complications from injections because of the proximity to breast tissue. The FDA has not approved dermal fillers for use in the decolletage — a body area that advisory panel members said was not well-defined. It is generally considered the triangular area that runs from the neck and clavicle area to in between the breasts. Agency officials and committee members noted that fillers are increasingly being used off-label to improve skin texture, crepiness, skin thickness, fine lines, and wrinkles in the decolletage. The most common fillers used in the neck and decolletage are made up of hyaluronic acid (HA), calcium hydroxylapatite (CaHA), or poly-L-lactic acid (PLLA), according to the American Academy of Dermatology Association (AADA). At a meeting on August 13, the FDA's General and Plastic Surgery Devices Panel was asked to review safety concerns, in anticipation that manufacturers will soon seek FDA approval of fillers for use in the decolletage area and need guidance on trial design and post-marketing studies. The agency raised the possibility that fillers could migrate from the injection site or form nodules and/or granulomas and interfere with mammograms, cause false positive readings on breast imaging or clinical exams, or impact breast feeding and lymphatic drainage. The committee — made up of dermatologists, plastic surgeons, oncologists, and radiologists — did not formally vote. The panel members agreed that patients who are breastfeeding or pregnant should be excluded from receiving injections because of the unknowns. Individuals with darker skin types or known wound-healing issues — both of whom might easily form keloids or nodules — or those with a history of radiotherapy, lymphoma, or other blood cancers were also seen as potentially higher risk populations, said panel chairman Hobart Harris, MD, MPH, the J. Engelbert Dunphy endowed chair in surgery at the University of California, San Francisco. Sandra R. Shuffett, MD, a breast imaging specialist in Lexington, Kentucky, and temporary panel member, said she was concerned that fillers could obscure tumors on breast imaging tests. 'My focus is to find a cancer as small as possible,' she said, adding that an unseen tumor could quickly grow larger, necessitating more serious treatment. The FDA has not received reports of problems with breast feeding or imaging but a post-approval study of Radiesse (CaHA) found that it obscured bone visualization. There have also been reports of lymph node enlargement near dermal filler injection sites. FDA reviewer Sung Yoon, MD, said at the meeting that the agency is 'not aware of specific reports where breast cancer was missed' because of dermal filler but noted that off-label use might mean less reporting of adverse events. Yoon told the panel that an analysis of the FDA's Medical Device Reporting database found 20 reports of serious injury events associated with the use of dermal fillers in the decolletage area since 2007 out of 186 reports related to unapproved upper body use. It is not possible to know how many decolletage procedures have been performed, she said. The FDA reported that an estimated 6.2 million dermal filler procedures were performed in 2024. Radiesse manufacturer, Merz Aesthetics, told the panel that, between 2018 and 2025, it received 44 reports of potential adverse events in the decolletage area, with none reporting migration of material or radiological interference. Radiesse is approved for decolletage wrinkles in the European Union and Canada. Social media may be fueling more use of fillers in the decolletage, especially among those taking GLP-1 receptor agonists for weight loss who are seeking 'to improve the skin rippling in the chest,' said Karol A. Gutowski, MD, a Chicago-based plastic surgeon who spoke to the committee. Representatives from dermatology and plastic surgery organizations said they had crafted guidelines for safe use of fillers in the decolletage but warned that filler use was often unregulated. 'Filler adverse events are likely under reported, and they're increasing in frequency as the popularity of injectable fillers increases,' said M. Laurin Council, MD, director of dermatologic surgery at Washington University School of Medicine, St. Louis, who spoke to the panel on behalf of the American Society for Dermatologic Surgery. Many panelists suggested women undergo baseline breast imaging before receiving filler in the decolletage area and collecting more data — such as on the volume of filler used during procedures — and added that perhaps a registry should be created. But some were skeptical. 'Probably 75% of these injections are done by non-medical people,' such as attendants at medical spas or storefront wellness centers, said panelist Alan Matarasso, MD, a New York City-based plastic surgeon and past president of the American Society of Plastic Surgeons. Matarasso said that manufacturers should be responsible for tracking their products, not clinicians. 'When these things are being done in strip malls and other places, we're not going to get the data that we need, because people are not going to cooperate with this,' said Gutowski. There is no approved method of removing dermal fillers. That gave some panel members pause. But dermatologists and plastic surgeons said that HA-based fillers could be dissolved with hyaluronidase. Even so, CaHA and PLLA fillers can't be dissolved and 'must break down naturally over time,' said Natalie Curcio, MD, MPH, a Nashville-based dermatologist who spoke to the panel on behalf of the AADA. Temporary committee member Karla V. Ballman, PhD, professor of biostatistics at the Mayo Clinic College of Medicine and Science, Rochester, Minnesota, said that patients should be informed, perhaps via wording on a product label that 'at the current time, there is no approved method of removal' of a filler. The FDA has periodically examined dermal filler safety. In July 2023, the agency updated its informational webpage to describe a new risk of delayed-onset inflammation near treatment sites that had been reported to occur following viral or bacterial illnesses or infections, vaccinations, or dental procedures. The webpage also lists common reactions such as bruising, redness, swelling, and pain. At the panel meeting, consumer advocate Diana Zuckerman, PhD, president of the National Center for Health Research, said that listing adverse events was not enough. 'Risks should be quantified with meaningful statistical data on the short term and long term risks,' said Zuckerman, who spoke during the open public hearing. 'FDA should require well designed and full clinical trials so that patients have the information they need to make informed decisions,' she said. 'FDA really appreciates the thoughtful discussion questions and recommendations that have been provided today, and we will certainly take all of these comments into consideration as we move forward,' said Cynthia Chang, PhD, an acting division director within the agency's Center for Devices and Radiological Health.
Fast Company
23 minutes ago
- Fast Company
Want to develop greater willpower and determination? A new study shows how to use the Navy SEAL 40% rule
Imagine you've worked hard. You've worked long. Mentally, physically you're done. But then I offer you $1,000 if you can keep going for another 10 minutes. And suddenly you're good to go. Hold that thought. Mental toughness. Determination. Willpower. Perseverance. However you describe it, the ability to push through mental and physical fatigue to achieve long-term goals is often what sets successful people apart. When others stop trying, the last person to give up—especially on themselves— is often the person who succeeds. But why do some people keep going when others won't? In part because they understand, if only intuitively, the 40% rule, a concept popularized by Dave Goggins in Jesse Itzler's book Living With a SEAL. The premise is simple. When our minds say we're exhausted, fried, and totally tapped out, we're really only 40% done: We still have 60% left in our tanks. So why do we stop? According to a new study published in Journal of Neuroscience, two brain regions activate when you feel mentally fatigued. (Physical fatigue is, in effect, mental fatigue. Your muscles don't give up when you're tired. Your mind gives up long before; otherwise you wouldn't stop until you physically collapse.) One culprit is the right insula, an area deep in the brain associated with feelings of fatigue. The other is the dorsal lateral prefrontal cortex, areas on both sides of the brain that control working memory. All of these areas work together to decide when it's time to avoid more cognitive effort—to decide when you're done. Except the decisions they make aren't particularly accurate. According to the researchers: Our study was designed to induce cognitive fatigue and see how people's choices to exert effort change when they feel fatigue, as well as identify locations in the brain where these decisions are made. However, there may be a discrepancy between perceptions in cognitive fatigue and what the human brain is actually capable of doing. Take incentives. When participants were fatigued, they were more likely to choose to pass up on higher levels of reward for more effort. The more fatigued they became, the greater the reward had to be. But with the right reward, they would—and obviously could—keep going. That makes intuitive sense. Deciding to give up is always a benefits/rewards decision. If you're creating a sales demo, you won't put in more effort unless you think it's worth it: If more work will create an appreciably better result, or if the demo's potential outcome is sufficiently great. Your brain weighs the effort against the outcome. That's why my offering you $1,000 for 10 more minutes makes you suddenly find mental or physical energy reserves you didn't think you had. Another factor is time. A study published in PLoS One found that people asked to pedal an exercise bike set at a certain resistance level as long as they could lasted about 12 minutes, until they said they could do no more. But when they were then asked to repeat a five second, maximum-effort power test, they could produce three times more power than they did during the endurance test. Their muscles weren't depleted. Their mind was depleted. Even if you think you're exhausted, cranking out another five seconds is (relatively) nothing. The endurance test is a different beast. Stuck on a bike, hamster-wheeling away, heart pounding and legs screaming, and not knowing how long the pain will last? Indefinite effort is physically and mentally draining, a combination that makes it much harder to keep pushing past what you perceive as your limit. Even though you could, if offered the right incentive. That's the primary takeaway. The ability to push through mental or physical fatigue is a trait you can definitely develop. But over the shorter term, if you want to keep going, the key is to find reasons—meaningful reasons—to stay the course. Getting in better shape so your clothes fit better is a worthwhile goal; getting in better shape so you can live a longer, healthier life and be there for your family is a meaningful goal. Finishing a sales demo because you'll make the call tomorrow is a worthwhile goal, but crafting a demo that will truly resonate with a potential long-term client—which will help you build a thriving business—is a meaningful goal. The key is to find a greater, more long-term 'why,' one that will outweigh the feeling that you're done. And to set time limits on your effort. Not knowing when you'll be done? You'll probably decide in, say, 30 minutes, even if you could go longer. But if you say, 'I'll give this one more hour,' now there's a limit, one you'll find the energy reserves to reach. When you think you're done, you really aren't. Your right insula and dorsal lateral prefrontal cortex have just decided you are. And you can just as easily—with the right incentives, and the right perspective—decide you're not done. — By Jeff Haden
